🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in India / NCT07743489
Starting soon Phase 3

RB-PDT for Fusarium Keratitis: The LUMIERE Study

NCT07743489 · tracked via the Priya Life Science India tracker
Sponsor
Stanford University
Phase
Phase 3
Started
2027-01
Last updated
2026-08-17

Condition(s) studied

Fusarium Keratitis

Investigational drug(s) / intervention(s)

Rose Bengal Photodynamic TherapySham RB-PDT

Rose Bengal Photodynamic Therapy: RB-PDT/sham RB-PDT will occur within 5 days of initial smear/culture. For Group 1, Rose Bengal (0.1% RB in 0.9% sodium chloride) will be applied in 3-minute intervals to the de-epithelialized cornea for 30 minutes followed by irradiation with a 6mW/cm2 custom-made green LED source for 15 minutes (5.4J/cm2). A second RB-PDT procedure and repeat smear/culture will occur one week after the first procedure, following the same protocol.

Sham RB-PDT: Participants in Group 2 will undergo a sham procedure using topical balanced salt solution and pen light covered with a green filter. Study participants will undergo repeat scraping and culture of the corneal ulcer 30 minutes after the assigned RB-PDT procedure. A second sham RB-PDT procedure and repeat smear/culture will occur one week after the first procedure, following the same protocol.

Study summary

This is a multicenter trial with recruitment planned at ophthalmology clinics specializing in corneal diseases in India, Brazil, and at Stanford University and Bascom Palmer Eye Institute in the United States. Fusarium keratitis is common in tropical and subtropical regions like Florida, India and Brazil, which will facilitate access to the required number of participants. The study aims to recruit a total of 434 participants (217 per group).

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Presence of culture positive fusarium fungal keratitis * Age over 18 years * Moderate to severe vision loss, defined as Snellen visual acuity of 20/40 (6/12) to 20/400 (6/120) * Corneal thickness ≥350 µm, as measured on AS-OCT * Basic understanding of the study as determined by the physician * Commitment to return for follow up visits Exclusion Criteria: * History of hypersensitivity to Rose Bengal * Evidence of concomitant infection on exam, gram stain, or confocal microscopy (i.e. herpes, both bacteria and acanthamoeba on gram stain) * History of intraocular surgery within the last three months\* * Impending or frank perforation at recruitment * Involvement of sclera at presentation * Presence of desmestocele at recruitment * Non-infectious or autoimmune keratitis * History of corneal transplantation * Pinhole visual acuity worse than 20/200 in the unaffected eye * Participants who are decisionally and/or cognitively impaired

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
Stanford University Palo Alto California
University of Miami - Bascom Palmer Eye Institute Miami Florida
Federal University of São Paulo São Paulo Brazil
Aravind Eye Care System Madurai Tamil Nadu
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07743489 on ClinicalTrials.gov ↗ ← All trials in India